Best Value Stocks to Buy for July 16th

Zacks highlights three Zacks Rank #1 value stocks—Braemar Hotels & Resorts (BHR), Consensus Cloud Solutions (CCSI), and Afya (AFYA)—citing earnings-consensus increases of +4.9%, +0.2%, and +6.5% over the past 60 days, respectively. Valuation screens are emphasized: BHR trades at a P/E of 8.35 vs. 12.80 industry, CCSI at 3.38 vs. 23.40, and AFYA at 10.90 vs. 26.90, each flagged as attractive on Value Score (A for BHR/CCSI; B for AFYA). This is primarily stock-specific positioning rather than an earnings/guidance event likely to move markets broadly.

Analysis

This is a low-conviction screening event, not a fresh catalyst, so the edge is mostly in dispersion rather than direction. The common setup is simple: cheap stocks can rerate only if the next print confirms that earnings revisions are durable; otherwise the market will treat this as a valuation trap menu and fade the screen.

AFYA looks the cleanest long because its economics are tied to a structurally constrained supply of medical education, which supports pricing power even when Brazil macro is noisy. The key second-order driver is FX/rates: if BRL stabilizes and local funding conditions ease, the market can pay a higher multiple for recurring tuition cash flow. The main falsifier is a renewed selloff in Brazilian real or another guidance reset on enrollment/collections.

BHR is a higher-beta rate-sensitive vehicle disguised as value. In the near term it can squeeze on any rotation into cyclicals, but the equity remains hostage to refinancing costs and the market’s view of leisure demand. CCSI is the most suspect: low P/E can coexist with structurally declining volume if legacy document workflows keep migrating away faster than SaaS offsets it. In that case, the multiple is not cheap enough to matter unless retention/ARR inflects over the next 1-2 quarters.

Key Decisions for Investors

• Small tactical long AFYA on weakness; best expressed as a 1-3 month trade into the next earnings update. Upside case is a rerating if revisions persist and BRL is stable; exit if Brazil FX weakens or guidance slips.
• Do not chase BHR as a stand-alone value long. If you want hotel beta, prefer HLT/MAR on any travel pullback; BHR’s levered equity makes the downside asymmetrically worse if rates stay elevated.
• Treat CCSI as a value-trap watch item, not a buy. Only reconsider on proof of durable ARR/retention inflection; absent that, the low multiple is likely compensating for secular decay.